The European approval for GSK's depemokimab joins recently announced data on vaccine efficacy and progress on 4-month viral treatments.

FDA has accepted the NDA for BMS's Iberdomide, an oral agent targetting relapsed/refractory multiple myeloma.

Roche. Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease. 2026 Feb 16. Accessed 2026 Feb 16.

Fujifilm’s £400m (US $547m) Teesside expansion adds 19,000L single-use capacity and an innovation center to boost global ...

Etalytics’ etaONE achieved a 21% cooling-electricity reduction in three months by autonomously orchestrating chillers, cooling towers, and pumps using real-time pressure and environmental data.

Suzanne Jansen, MSc, PharmD, ICON, says early-phase clinical success depends on flexible, simple formulations that support ...

Phlow will manufacture epinephrine API in Virginia while Fresenius Kabi formulates and fills finished doses in existing US ...

Carter emphasizes that women are currently serving as primary “thought leaders” in the advancement of precision medicine . In ...

PharmTech spoke with women working in the pharmaceutical industry about the innovations they are seeing in bio/pharma and the ...

Iambic’s physics-informed NeuralPLexer is intended to enhance protein–ligand modeling, enabling broader exploration of ...

Márcio Temtem, Hovione, discusses how to tackle pharma complexity via regional growth in the US, Ireland, and Portugal, using digital tools to accelerate development.

Marcio Temtem, vice president, Strategic Business Management, Hovione, addresses molecule complexity, speed, and ...